Search Videos and More
Video
Stefania Morganti, MD discusses ctDNA study
Ultrasensitive detection of minimal residual disease using ctDNA can help predict the duration of response to HER2 targeted therapy in patients with metastatic breast cancer, according to a study presented by Stefani Morganti, MD, of Dana-Farber Cancer Institute.
Video
Ann Partridge, MD discusses YES study
Breast cancer survivors who used a novel mobile health intervention to self-manage post-treatment symptoms were able to improve their quality of life and reduce the burden of common symptoms, according to results of the YES study presented by Ann Partridge, MD, of Dana-Farber Cancer Institute.
News
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
News
Dana-Farber Research News 12.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.
News
Mobile Health Tool Helps Improve Quality of Life For Young Breast Cancer Survivors
dolescent and young adult breast cancer survivors who used a novel mobile health (mHealth) intervention to self-manage post-treatment symptoms and concerns were able to improve their quality of life and reduce the burden of common symptoms compared to patients who received usual care, according to results from a new clinical trial being reported at the 2025 San Antonio Breast Cancer Symposium (SABCS).
News
Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer
A new study from Dana-Farber Cancer Institute finds that patients with NUT carcinoma (NC), an aggressive squamous cell lung or head and neck cancer, often face delays in diagnosis—delays that can prevent them from receiving the right treatment or joining clinical trials.
News
Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial
News
Childhood leukemia care puts one in three families at risk of poverty
Dana-Farber-led study shows families develop food, housing insecurity or income loss during cancer treatment
News
Chemo-free Regimens Show Promise, Could Redefine Care for B-Cell Lymphomas
Dana-Farber studies of chemo-free, targeted-immunotherapy combinations show rapid, deep responses and potential for time limited care in B cell lymphomas
News
Dana-Farber Cancer Institute drives deep remissions in Waldenstrom’s with targeted, time limited therapies
Early phase results from Dana Farber suggest chemo free, time limited strategies may reduce the need for lifelong treatment in Waldenström’s
News
Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)
Pivotal phase III VERONA trial results presented at the American Society of Hematology annual meeting show no overall survival improvement, but potential for sub-group benefit and no added side effects.
News
Sickle-cell disease associated with early onset of clonal hematopoiesis, a precancerous condition
The discovery, led by researchers at Dana-Farber, could pave the way for interventions to reduce the risk of blood cancers among people with sickle-cell disease.